Cette année sera-t-elle une année fructueuse pour la réduction des risques du Portugal?

Actualités

Cette année sera-t-elle une année fructueuse pour la réduction des risques du Portugal?

11 avril 2014

La réduction des risques au Portugal a constitué une réponse complète et inclusive vis-à-vis de la consommation de drogues.

Pour en savoir plus, veuillez lire les informations ci-dessous (en anglais).

Abonnez-vous à l'Alerte mensuelle de l'IDPC pour recevoir des informations relatives à la politique des drogues.

Around seventy experts met under the flag of the Portuguese National Harm Reduction Network to discuss the state of Harm Reduction in Portugal.

In late November last year, the Portuguese National Harm Reduction Network – R3 - organised its third annual Conference on “Harm Reduction in a Crisis Context”, with around 70 participants, in the Portuguese city of Porto,.

R3 was founded in 2004 - a network of professionals and experts who represent around half of the Portuguese harm reduction projects intervening in drug use. Some of its main objectives are: to contribute to the development of effective and evidence-based practice; to promote knowledge sharing, and debate relevant issues for action; and to create favourable conditions for the participation of people who use drugs, in the decision-making and intervention processes.

During 2013, a number of harm reduction services were obliged to cease operations for several months. A new state body, SICAD, emerged (Intervention Service on Addictive Behaviours and Dependences), and the official structure responsible for implementing Portuguese drug policy changed, together with administrative and funding procedures.

At the conference, an R3 representative presented data on the state of play within Harm Reduction Services, specifically the funding for needle exchange programmes.

Harm reduction and opioid substitution treatments, in Portugal, have contributed to a comprehensive and inclusive response to drug use.

Click here to read the full article.

Keep up-to-date with drug policy developments by subscribing to the IDPC Monthly Alert.